Travere Therapeutics, Inc.
TVTX
$14.92
$0.352.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -321.55M | -351.45M | -145.91M | -161.13M | -111.40M |
| Total Depreciation and Amortization | 43.56M | 40.95M | 41.19M | 41.79M | 38.53M |
| Total Amortization of Deferred Charges | 1.73M | 1.72M | 1.72M | 1.72M | 1.72M |
| Total Other Non-Cash Items | 101.81M | 99.88M | -124.38M | -192.95M | -183.40M |
| Change in Net Operating Assets | -63.02M | -63.32M | -61.48M | -7.34M | -25.48M |
| Cash from Operations | -237.48M | -272.23M | -288.86M | -317.91M | -280.02M |
| Capital Expenditure | 0.00 | 561.00K | 551.00K | 630.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.33M | 162.12M | 249.33M | 197.08M | 55.78M |
| Cash from Investing | 99.33M | 162.68M | 249.88M | 197.71M | 55.78M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 150.52M | 15.39M | 14.97M | 16.71M | 210.20M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.10M | -14.96M | -15.22M | -15.48M | 8.55M |
| Cash from Financing | 139.42M | 427.00K | -253.00K | 1.23M | 218.75M |
| Foreign Exchange rate Adjustments | -913.00K | 1.28M | 649.00K | 840.00K | 1.98M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 359.00K | -107.84M | -38.58M | -118.13M | -3.51M |